Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of the PD-1 Antibody Nivolumab in Combination With Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD)

X
Trial Profile

A Phase I/II Study of the PD-1 Antibody Nivolumab in Combination With Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Nivolumab (Primary) ; Aspirin
  • Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Apr 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
    • 30 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
    • 15 Jun 2023 Results assessing the toxicity and preliminary efficacy of the combination in patients with relapsed HL and LBCL presented at the 28th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top